The Conversation (0)
Immunovaccine Inc. (TSXV:IMV), a clinical stage vaccine company, has obtained a loan of $5 million from the Province of Nova Scotia, to be used to fund a portion of working capital through 2016.
Immunovaccine Inc. (TSXV:IMV), a clinical stage vaccine company, has obtained a loan of $5 million from the Province of Nova Scotia, to be used to fund a portion of working capital through 2016.
As quoted in the press release:
Immunovaccine currently has several vaccine programs in development, including two clinical stage cancer vaccines which have both demonstrated positive immune response and safety results in human studies. The company announced in July that it will collaborate with Canada’s NCIC Clinical Trials Group to conduct a Phase II study of its lead cancer vaccine, DPX-Survivac, in patients with advanced ovarian cancer.Â
Click here for the full press release by Immunovaccine Inc. (TSXV:IMV)